Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822587 · ClinicalTrials.gov registry record · Phase 2
Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT01822587 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 181 participants.
The verdict
NCT01822587, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
The investigators' recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine addicted persons. The investigators will attempt to augment this effect by a) doubling the number of propranolol-medicated cocaine cue exposure (CCE) retrieval sessions and b) increasing the dose of propranolol. It is expected that propranolol treated groups, relative to placebo treated groups, will evidence greater reduction of craving, cue reactivity and cocaine use during follow-up cocaine cue exposures. Also, these effects will be greater for those who receive 80mg of propranolol as opposed to 40mg.
Interventions
- DRUG Placebo
- DRUG Propranolol, 40 mg
- DRUG Propranolol, 80 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2013-09 |
| Est. Completion | 2018-11-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822587
The ClinicalTrials.gov registry entry for NCT01822587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01822587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01822587 about?
NCT01822587 is a clinical study titled "Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving". The investigators' recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine addicted persons. The investigator...
What is the current status of trial NCT01822587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2013-09. Estimated completion is 2018-11-05.
What interventions are being tested in trial NCT01822587?
The interventions under investigation include: Placebo (DRUG), Propranolol, 40 mg (DRUG), Propranolol, 80 mg (DRUG).
Who is sponsoring clinical trial NCT01822587?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.